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A COST-EFFECTIVENESS ANALYSIS OF ACE
INHIBITOR TRANDOLAPRIL AS A
PREVENTATIVE TREATMENT OF HEART-
FAILURE PROGRESSION
Lilliu H1, Le Pen C1, Lamiraud K1,Wittenberg W2
1Clp-santé, Paris, France; 2ABBOTT GmbH &Co KG,
Ludwigshafen, Germany
OBJECTIVES: This study aimed at performing an eco-
nomic analysis in an American setting of the use of
Angiotensin Converting Enzyme (ACE) inhibitor tran-
dolapril in postinfarction patients as a preventative agent
of heart failure (HF) progression, based on the TRACE
trial’s individual data. METHODS: The TRACE study
was a prospective placebo-controlled clinical trial de-
signed to determine the long-term effect of trandolapril
in postinfarction patients with left ventricular dysfunc-
tion. 1749 patients were followed from 1992 to 1995.
Our analysis was incremental and was conducted from a
Payer Perspective in a US setting. Unit costs were attached
to the use of resources (mean costs per Diagnosis Related
Groups for hospitalizations and Average Wholesale Prices
for concomitant dugs). The primary effectiveness crite-
rion was the progression of HF as deﬁned in the clinical
trial, i.e. death from HF or hospitalization for HF or HF
necessitating open-label ACE inhibitor administration.
Uncertainty surrounding the estimate of the CE ratio was
taken into account through a non-parametric bootstrap
analysis. RESULTS: Trandolapril cost amounted to
US$550 and concomitant drugs were valued to US$2386
for trandolapril treated patients versus US$1975 for
placebo treated patients. On the other hand, hospitaliza-
tions cost was US$6671 for trandolapril patients versus
US$7979 for placebo patients. The total mean medical
cost was slightly lower in the active therapy group,
US$9607 versus US$9954, p = 0.5305. 14.04% of tran-
dolapril patients versus 19.70% of placebo patients expe-
rienced a HF progression, p = 0.003. Among 5,000
bootstrap re-samples, ACE inhibitor therapy was cost
saving in 66.7% of the cases and cost-effective in 33.3%.
The cost per avoided HF progression reached US$8860
among the samples with both cost and effectiveness 
differentials positive. CONCLUSIONS: These results
obtained in an American setting could be considered as
highly cost-effective. From a methodological standpoint,
it raises the issue of CE analysis when cost differentials
are close to zero.
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PRESCRIPTION DRUG INFORMATION: A
SURVEY OF THE GENERAL POPULATION IN
SPAIN
Badia X1, Magaz S2, Gutierrez L2
1Health Outcomes Research Europe Group, Barcelona, Spain;
2Health Outcomes Policy and Economics, Barcelona, Spain
Controversy exists on the possible relaxation of the EU
regulations on the prescription drug information given
directly to patients, and Europeans have the right to voice
their opinions. OBJECTIVES: To know the views of the
Spanish population on currently available prescription
drug information and additional information they would
like access to. METHODS: A population-based telephone
survey of 1069 people over 15 and representative of the
Spanish population was conducted between February 
and March 2003. The sample was randomly selected
using proportional stratiﬁed sampling by age, gender and
Autonomous Regions, according to the Spanish National
Statistics Institute data for these variables. The question-
naire was elaborated based on a review of the legislation
and literature and on a focus group made up of repre-
sentatives who provide medical information to patients.
RESULTS: The general population normally receives
information on prescription drugs from package inserts
(75.9%), physicians (54.9%), pharmacists (17.4%) or
nurses (6.7%). Other possible sources of information
(medical journals, Internet, patient associations, family/
friends) are consulted by less than 3% of the population.
Furthermore, only 11.6% of the Spanish population state
that their physicians provide them with information on
alternative prescription drugs, so that patients feel inca-
pable of exercising their right to participate in treatment
selection. A total of 45.9% of the population would like
their physicians to provide written information (leaﬂets)
on drugs prescribed, and 52.9% demand greater access
to prescription drug information from sources other than
Health care professionals. A total of 45.6% think that
pharmaceutical companies should be allowed to provide
reliable, comprehensive and supervised information on
their prescription drugs, through leaﬂets handed out by
physicians or pharmacists. The perceived beneﬁts out-
weigh the perceived risks. CONCLUSIONS: The general
population in Spain state that they are insufﬁciently
informed on prescription drugs and are interested in
gaining access to wider high-quality information, includ-
ing that from the pharmaceutical industry.
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CHARACTERIZATION OF POLYPHARMACY
ISSUES AND SUBSEQUENT INTERVENTION IN
A POPULATION OF ELDERLY COMMUNITY-
DWELLING INDIVIDUALS
Weishaar R1, Erwin G2, Dybicz S2, Molotsky S2
1Omnicare Clinical Research,Troy, NY, USA; 2Omnicare Senior
Health Outcomes, King-of-Prussia, PA, USA
OBJECTIVES: To identify and characterize medication-
related issues among elderly community-dwelling indi-
viduals with polypharmacy. To contact physicians about
advancing quality care through modiﬁcation of complex
drug regimens, either by eliminating unnecessary drugs 
or by revising therapy to reﬂect standards of practice.
METHODS: An intervention program was conducted in
retirees from a large corporation. Individuals with 9 or
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more different medications present in their pharmacy
claims data over a 3-month period were selected. Cases
were developed by combining demographic, medical, and
pharmacy claims data, and sent for review by Omnicare’s
consultant pharmacists. Based on quantitative and qual-
itative review, recommendations were made on behalf of
each retiree at moderate to high risk and the appropriate
physician contacted by telephone or fax. RESULTS: A
total of 488 polypharmacy cases were identiﬁed from a
sample of 14,000 retirees, of which 309 were eligible 
for inclusion. An average of 12 medications was pre-
scribed to these individuals. A total of 61.8% had safety,
quality, or cost issues of moderate to high risk requir-
ing intervention. In 49.1% (152) of all reviewed cases, 
medication safety issues were present. Most instances
involved an inappropriate medication for use in the
elderly. Recommendations for improved management of
coronary heart disease and stroke were addressed in
34.0% (105) and 19.4% (60) of the cases, respectively.
Other key recommendations involved aspirin use, Cox-2
Inhibitor use in retirees with heart disease, medications
associated with increased risk of falls and fractures, and
untreated osteoporosis. Recommendations were accepted
by over half of responding physicians. CONCLUSIONS:
Inappropriate medication use continues among elderly
persons treated with multiple agents. Pharmacist inter-
vention with physicians can improve prescribing in this
population.
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THE ANTIBIOTIC USE IN POLAND IN THE
TREATMENT OF COMMUNITY-ACQUIRED
PNEUMONIA IN ADOLESCENTS AND ADULTS
VERSUS CURRENT GUIDELINES
Cel M, Krzyzanowska AM, Glogowski CA, Gierczynski JM
GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland
OBJECTIVES: The aim was to compare prescription 
patterns in Poland in treatment of community-acquired
pneumonia (CAP), matched with current guidelines and
their ﬁnancial consequences. METHODS: Epidemiologi-
cal data from Alexander Project microbiological study
were used. The Dataview Medical Database IMS Health
for Poland, was the source of medical data on provided
medical services and prescriptions made out by out-
patient clinic doctors. These were compared with guide-
lines of Polish Working Group for Standards of Rational
Therapy and Prophylaxis of Infections. Drugs prices were
taken from offer of leading wholesaler. RESULTS: CAP
makes up of 4% of all respiratory system infections, 20%
of them require hospitalisation. The Alexander Project
shows that causes of CAP are: S. pneumoniae (7–76%),
H. inﬂuenzae (1–16%), S. aureus (0–4%), Gram (-) bac-
teria (0–28%), non-typical bacteria such M. pneumoniae
(0–24%) C. pneumoniae and Legionella sp. (0–15%). 
In 2002, for patients aged 12–64 years, 302.656 visits
(234.451—ﬁrst visits, 68.206—follow-up visits) because
of CAP were registered, in 254.179 (i.e. 84%) cases pre-
scriptions for antibiotics were made-out. The percentages
of antibiotics were following: 24.1% oral macrolid, 4.4%
injected macrolid, 24.2% oral cephalosporin, 16.4%
injected cephalosporin, 14.4% oral wide-spectrum peni-
cillin, 11.6% oral tetracycline, 10.2% aminoglycoside,
2.2% oral ﬂuoroquinoline, 0.2% co-trimoxasole (com-
bined treatment 7.7%). Total cost of antibiotics was
€4.549 million. For ﬁrst visits this cost amounted to
€4.043 million and for follow-up visits to €0.507 million.
The cost of treatment according to the guidelines was esti-
mated, depending on chosen option, at €3.260 to €6.713
million. CONCLUSIONS: Analysis shows that prescrip-
tion patterns in CAP, differs from the guidelines. 45% of
cases were treated in way foreseen for non-typical CAP,
whereas epidemiological data shows that real number of
such cases does not exceed 20%. Treatment based on rec-
ommendations would not bring savings, but would slow
down the growth of bacterial resistance.
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PATTERNS OF USE OF COXIBS AND NON-
SELECTIVE NSAIDS IN THE ELDERLY
POPULATION OF QUEBEC (CANADA)
Moride Y1, Ducruet T2, Rochon S3, Lavoie F3
1Université de Montréal, Montréal, QC, Canada; 2Boreal
Primum inc, Montréal, QC, Canada; 3Pﬁzer Canada Inc,
Kirkland, QC, Canada
Few data have been published on the patterns of use
COX-2 inhibitors (coxibs)and non-selective NSAIDs in
“real-life” setting; a major determinant of effectiveness.
OBJECTIVES: 1) To assess the rate of persistency of
coxibs over the ﬁrst 3 months of treatment in the elderly
population; 2) to determine the rate of switching; 3) 
to identify characteristics associated with persistency.
METHODS: A retrospective cohort study was conducted
in a cumulative incidence random sample of members
(age 65+) of the Quebec drug plan who initiated a treat-
ment with celecoxib (n = 14,396), rofecoxib (n = 6,120)
or non-selective NSAIDs (n = 1,202) between January 1st
and August 31st 2000. All medical services and prescrip-
tions received by these patients during the previous year
were obtained through linkage with the Quebec health
services databases. Cox proportional hazard was used to
identify factors associated with persistency. RESULTS:
Over the ﬁrst 3 months of treatment, the median 
duration of use was 22 days for celecoxib, 21 days for
rofecoxib, and 12 days for non-selective NSAIDs. On
average, 24.2% of incident celecoxib users and 17.3% 
of rofecoxib users were treated for more than 3 months,
compared to 10.2% of non-selective NSAID users.
Switches were not frequent: 4.1% of celecoxib users
switched to rofecoxib, and 2.3% to non-selective
NSAIDs. Of rofecoxib users, 2.9% switched to celecoxib
and 2.4% to non-selective NSAIDs. Factors signiﬁcantly
associated with persistency were: celecoxib (OR = 1.19;
1.11–1.27), use of gastroprotective agents at treatment
initiation (OR = 1.22; 1.16–1.27) or during follow-up
